A global leader in personalised human tissue repair.
Shenzhen Excellent Technology Co., Ltd. (Excellent MedTech) is a pioneer in patient-matched 3D-printed titanium reconstruction and regenerative medicine. Founded to address the largest unmet needs in skeletal and soft-tissue repair, we have grown from a single-product company into a three-platform regenerative medicine enterprise.
Restore form. Restore function. Restore the future of tissue regeneration.
Every implant we ship is engineered to do three things: match the patient's anatomy 1-to-1, withstand decades of physiological load, and serve as a platform for the next generation of regenerative therapies. We exist to close the gap between what standard implants can do and what each patient actually needs.
The human skeletal system is the most architecturally complex structure in the body. Treating it requires more than off-the-shelf plates and screws. It requires a complete patient-data-to-implant pipeline that respects the individuality of every fracture, defect, and surgeon.
From a single implant to a three-platform regenerative enterprise.
Founded with a singular focus: personalised human skeletal repair through additive manufacturing. Core team brings together biomedical engineering, clinical medicine, and materials science.
Early clinical collaborations with the Fourth Military Medical University and Southern Medical University affiliated hospitals validate the technology in a real-world setting.
By 2018, the dataset reaches 100+ cases — and the complication rate is already in the low single digits, confirming the original hypothesis.
Recognised by the Guangdong Provincial Government with the Science and Technology Invention Award (Second Prize) for core technical innovation.
Three integrated R&D platforms — additive manufacturing, protein engineering, tissue engineering — form the basis of the long-term regenerative strategy.
Quality system certified for the production of Class III medical devices. Lay the foundation for international regulatory submissions.
First GMP factory operational; 5,000 m² modern additive manufacturing and biomanufacturing centre in planning to meet global demand.
International expansion: regulatory submissions in EU, US, UK, Canada, Australia, Japan, and Brazil. KOL network activated across EANS, AOCMF, EuroCMF.
Technology-driven. Standards-led. Market-validated. Team-excellent.
Technology-driven
Three proprietary R&D platforms and 60+ IP rights form an integrated technology engine.
Standards-led
Co-author of 10 national guidelines, 2 expert consensuses, and 2 group standards — shaping the industry.
Market-validated
5,000+ cases across 500+ hospitals. 3 months to obtain reimbursement coding. 1 month for multi-province pricing.
Team excellent
Cross-disciplinary team with national and provincial-level awards, including National Science & Technology Progress Award winners.
Excellence in every dimension.
Headquartered in Shenzhen. Active worldwide.
- 10B Kechuang Building, Quanzhi Tech Innovation Park, Bao'an District
- Shenzhen Center for Advanced Additive Manufacturing & Biomanufacturing
- 800 m² operational + 5,000 m² expansion in planning
- CE-MDR Class III in progress (TÜV SÜD / DEKRA target)
- KOL network: Charité, MHH, LMU, AP-HP, Niguarda, Vall d'Hebron
- Engagement: EANS · AOCMF · EuroCMF
- FDA 510(k) pathway scoping (CDRH)
- Engagement: AANS · CNS · NREF · AAOMS
- Distribution: GPOs and academic hospital channels
Want to know more?
Read about our leadership team, manufacturing facility, or the history behind Excellent MedTech.